AbbVie (NYSE:ABBV) Shares Down 1.1% – Time to Sell?

AbbVie Inc. (NYSE:ABBV)’s stock price was down 1.1% during mid-day trading on Tuesday . The stock traded as low as $250.10 and last traded at $251.45. Approximately 6,849,466 shares changed hands during mid-day trading, a decline of 5% from the average daily volume of 7,211,684 shares. The stock had previously closed at $254.31.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said its ongoing post-market study for CoolSculpting Elite showed encouraging results, strengthening the outlook for its aesthetics business and suggesting the franchise could remain a meaningful growth driver. AbbVie’s CoolSculpting Elite Study Update Strengthens Aesthetics Outlook
• Positive Sentiment: AbbVie was highlighted in dividend-focused commentary as one of the market’s more reliable income stocks, reinforcing the investment case around its strong cash flow, defensive profile, and shareholder returns. 3 Dividend Stocks to Buy Hand Over Fist in July
• Positive Sentiment: Recent coverage also pointed to AbbVie’s venetoclax data in chronic lymphocytic leukemia as another sign that the company’s core pharmaceutical pipeline remains productive, supporting long-term earnings visibility. AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment
• Neutral Sentiment: Analysts and comparison pieces this week largely framed AbbVie as a strong long-term healthcare name versus peers like Johnson & Johnson, but these were more valuation and portfolio discussions than fresh company-specific catalysts. J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
• Negative Sentiment: One analyst note trimmed its FY2027 EPS estimate slightly, which is a mild headwind, though the change was small and did not materially alter the broader earnings outlook for AbbVie.

Analyst Ratings Changes

A number of research analysts recently weighed in on ABBV shares. Evercore set a $235.00 target price on AbbVie in a report on Friday, May 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Canaccord Genuity Group increased their price objective on shares of AbbVie from $265.00 to $273.00 and gave the company a “buy” rating in a research report on Tuesday, June 23rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.81.

AbbVie Stock Up 3.9%

The stock has a fifty day moving average price of $217.86 and a two-hundred day moving average price of $219.76. The company has a market cap of $460.92 billion, a price-to-earnings ratio of 128.51, a P/E/G ratio of 0.83 and a beta of 0.32.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.46 earnings per share. Analysts predict that AbbVie Inc. will post 14.28 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Wednesday, July 15th. AbbVie’s payout ratio is presently 340.89%.

Hedge Funds Weigh In On AbbVie

Hedge funds have recently added to or reduced their stakes in the stock. Bank of Jackson Hole Trust raised its stake in AbbVie by 0.6% in the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after purchasing an additional 44 shares in the last quarter. Eclectic Associates Inc. ADV grew its stake in AbbVie by 0.8% during the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after buying an additional 45 shares in the last quarter. Imprint Wealth LLC increased its holdings in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the period. Hardin Capital Partners LLC increased its holdings in AbbVie by 1.4% in the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after buying an additional 46 shares during the period. Finally, Dogwood Wealth Management LLC raised its position in shares of AbbVie by 10.8% in the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock valued at $108,000 after buying an additional 46 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.